Table 1 Comparison of baseline characteristics between the registry cohorts versus relevant studies providing evidence on secondary stroke prevention in atrial fibrillation

Age (years) mean, ±SD

77.7 (±9)

77.6 (±8)

75.1(± 8)

71 (±7)

72 (± 8)

70.2

81.5 (±8)

70 ± 9

70 (±9)^a

70.1 (±9.7)^a

71 (median)^a

(IQR 64–77)

Sex

 Male

7,312 (46%)

764 (41.8%)

398 (48.1%)

395 (59%)

430 (47%)

4,430 (66%)

531 (55%)

3,277 (59%)

2,279 (63%)^a,†

2,152 (63%)^a,†

4,538(61%)^a,†

 Female

8,574 (53%)

1,064 (58%)

429 (51.9%)

274 (41%)

486 (53%)

2,276 (34%)

442 (45%)

2,322 (41%)

1,344 (37%)^a,†

1,284 (37%)^a,†

2,930(39%)^a,†

Risk factors

 Hypertension

12,679 (80%)

1,444 (79%)

660 (79.8%)

294 (44%)

506 (55%)

5,522 (82%)

528 (54%)

4,837 (86%)

2,783 (77%)^a,†

2,858 (83%)^a,†

6,343 (85%)^a,†

 Diabetes mellitus

4,371 (27%)

530 (29%)

240 (29%)

87 (13%)

144 (16%)

1,429 (21%)

129 (13%)

1,096 (20%)

816 (22%)^a,†

902 (26%)^a

5,695 (24%)^a,†

Proportion of Strokes or TIAs within the study population

100%

100%

100%

100%

100%

15% (n = 1,006)

13% (n = 124)

14% (n = 764)

20% (n = 3,623)

19% (n = 3,436)

52% (n = 7,468)

Comparison of agents

–

–

–

Warfarin vs. placebo and aspirin vs. placebo

Indobufen^b vs. warfarin

Aspirin + clopidogrel vs. warfarin

Warfarin vs. aspirin

Apixaban vs. aspirin

Dabigatran vs. warfarin

Apixaban vs. warfarin

Rivoroxaban vs. warfarin